| Understanding and managing methotrexate nephrotoxicity BC Widemann, PC Adamson The oncologist 11 (6), 694-703, 2006 | 857 | 2006 |
| Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study YP Mossé, MS Lim, SD Voss, K Wilner, K Ruffner, J Laliberte, D Rolland, ... The lancet oncology 14 (6), 472-480, 2013 | 779 | 2013 |
| Declining childhood and adolescent cancer mortality MA Smith, SF Altekruse, PC Adamson, GH Reaman, NL Seibel Cancer 120 (16), 2497-2506, 2014 | 714 | 2014 |
| Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy TA Glauser, A Cnaan, S Shinnar, DG Hirtz, D Dlugos, D Masur, PO Clark, ... New England Journal of Medicine 362 (9), 790-799, 2010 | 693 | 2010 |
| Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration TJ Walsh, MO Karlsson, T Driscoll, AG Arguedas, P Adamson, ... Antimicrobial agents and chemotherapy 48 (6), 2166-2172, 2004 | 405 | 2004 |
| High‐dose methotrexate‐induced nephrotoxicity in patients with osteosarcoma: incidence, treatment, and outcome BC Widemann, FM Balis, B Kempf‐Bielack, S Bielack, CB Pratt, S Ferrari, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 385 | 2004 |
| Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children’s Oncology Group Study YP Mossé, SD Voss, MS Lim, D Rolland, CG Minard, E Fox, P Adamson, ... Journal of Clinical Oncology 35 (28), 3215, 2017 | 374 | 2017 |
| Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months TA Glauser, A Cnaan, S Shinnar, DG Hirtz, D Dlugos, D Masur, PO Clark, ... Epilepsia 54 (1), 141-155, 2013 | 286 | 2013 |
| Shortening the timeline of pediatric phase I trials: the rolling six design JM Skolnik, JS Barrett, B Jayaraman, D Patel, PC Adamson Journal of Clinical Oncology 26 (2), 190-195, 2008 | 284 | 2008 |
| Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents TJ Walsh, PC Adamson, NL Seibel, PM Flynn, MN Neely, C Schwartz, ... Antimicrobial agents and chemotherapy 49 (11), 4536-4545, 2005 | 284 | 2005 |
| Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study JLG Bender, PC Adamson, JM Reid, L Xu, S Baruchel, Y Shaked, ... Journal of clinical oncology 26 (3), 399-405, 2008 | 270 | 2008 |
| Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study EA Raetz, MS Cairo, MJ Borowitz, SM Blaney, MD Krailo, TA Leil, JM Reid, ... Journal of Clinical Oncology 26 (22), 3756, 2008 | 250 | 2008 |
| A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study M Bond, ML Bernstein, A Pappo, KR Schultz, M Krailo, SM Blaney, ... Pediatric blood & cancer 50 (2), 254-258, 2008 | 238 | 2008 |
| Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group S Malempati, B Weigel, AM Ingle, CH Ahern, JM Carroll, CT Roberts, ... Journal of Clinical Oncology 30 (3), 256, 2012 | 209 | 2012 |
| Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report M Fouladi, JR Park, CF Stewart, RJ Gilbertson, P Schaiquevich, J Sun, ... Journal of Clinical Oncology 28 (22), 3623, 2010 | 198 | 2010 |
| A phase I clinical trial of the hu14. 18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's … KL Osenga, JA Hank, MR Albertini, J Gan, AG Sternberg, J Eickhoff, ... Clinical cancer research 12 (6), 1750-1759, 2006 | 192 | 2006 |
| Rituximab for high-risk, mature B-cell non-Hodgkin’s lymphoma in children V Minard-Colin, A Aupérin, M Pillon, GAA Burke, DA Barkauskas, ... New England Journal of Medicine 382 (23), 2207-2219, 2020 | 187 | 2020 |
| Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome BC Widemann, FM Balis, AR Kim, M Boron, N Jayaprakash, A Shalabi, ... Journal of clinical oncology 28 (25), 3979, 2010 | 186 | 2010 |
| A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study TM Horton, D Pati, SE Plon, PA Thompson, LR Bomgaars, PC Adamson, ... Clinical cancer research 13 (5), 1516-1522, 2007 | 173 | 2007 |
| Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer. MA Smith, PC Adamson, FM Balis, J Feusner, L Aronson, RF Murphy, ... Journal of clinical oncology 10 (11), 1666-1673, 1992 | 171 | 1992 |
